Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 4:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Treatment interruption Clear all
Completed Phase 3 Interventional

Study of Clevidipine Assessing Its Preoperative Antihypertensive Effect in Cardiac Surgery (ESCAPE-1)

NCT00093249
View directory record Official record
Conditions
Hypertension
Interventions
clevidipine, placebo
Drug
Lead sponsor
The Medicines Company
Industry
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
12
States / cities
Birmingham, Alabama • Los Angeles, California • Hudson, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2014 · Synced Sep 13, 2026, 4:44 PM EDT
Completed Phase 2 Interventional

Early Directed Physical Therapy in the Management of Mechanically Ventilated Patients in a Medical Intensive Care Unit

NCT00322010
View directory record Official record
Conditions
Mechanically Ventilated Patients
Interventions
early PT OT
Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 17, 2014 · Synced Sep 13, 2026, 4:44 PM EDT
Completed Phase 4 Interventional

Pilot Study Evaluating Interruption of Enfuvirtide (Fuzeon, T20) in Patients With Enfuvirtide Resistance

NCT00187551
View directory record Official record
Conditions
HIV Infections
Interventions
Interruption of enfuvirtide, enfuvirtide interrupton
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 9, 2011 · Synced Sep 13, 2026, 4:44 PM EDT
Completed Not applicable Interventional

Recurrent Low Back Pain: Linking Mechanism to Outcomes (RCT)

NCT01360359
View directory record Official record
Conditions
Low Back Pain
Interventions
Core Stabilization, Trunk Motion and Fitness
Other
Lead sponsor
Drexel University
Other
Eligibility
18 Years to 65 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • West Chester, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 10, 2015 · Synced Sep 13, 2026, 4:44 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Changes in Abdominal Tissues Induced by Magnetic Device - CT Evaluation

NCT03545646
View directory record Official record
Conditions
Fat Burn
Interventions
Treatment with High Intensity Focused ElectroMagnetic system
Device
Lead sponsor
BTL Industries Ltd.
Industry
Eligibility
22 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
2
States / cities
Macon, Georgia • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 13, 2020 · Synced Sep 13, 2026, 4:44 PM EDT
Completed No phase listed Observational

Controlling Acute or Early HIV Infection With Antiretroviral Drugs, Without a Candidate Vaccine.As Reported Previously, the Candidate Vaccie Was Not Provided by the Maufacturer as Promised

NCT00238459
View directory record Official record
Conditions
HIV Infections
Interventions
Patients elected to take licensed drugs. The vaccine was not provided for evaluation, multiple licensed drugs not randomized, multiple licensed antiretroviral drugs; not randomized, Intended vaccine not provided, Licensed drugs provided, but were not investigated
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 19, 2013 · Synced Sep 13, 2026, 4:44 PM EDT
Recruiting Not applicable Interventional

Perturbation Training Reduces Falls in People With Alzheimer's Disease (AD)

NCT05205980
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Perturbation training
Behavioral
Lead sponsor
Georgia State University
Other
Eligibility
65 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Valdosta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Sep 13, 2026, 4:44 PM EDT
Withdrawn Phase 1 Interventional

Broadly Neutralizing Antibodies 3BNC117-LS & 10-1074-LS to Prevent Relapse During ATI

NCT05079451
View directory record Official record
Conditions
HIV Infections
Interventions
3BNC117-LS, 10-1074-LS
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 6, 2023 · Synced Sep 13, 2026, 4:44 PM EDT
Terminated Phase 2 Interventional Results available

Sorafenib in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in at Least the Second Remission

NCT00522301
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
sorafenib tosylate, immunoenzyme technique, immunohistochemistry staining method, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 28, 2016 · Synced Sep 13, 2026, 4:44 PM EDT
Withdrawn Not applicable Interventional

Transoral Gastric Volume Reduction as an Intervention for Weight Management

NCT02578836
View directory record Official record
Conditions
Obesity, Overweight, Weight Loss
Interventions
Fogel Gastroplasty
Procedure
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Sep 13, 2026, 4:44 PM EDT
Terminated Phase 1 Interventional

Melphalan With BBBD in Treating Patients With Brain Malignancies

NCT00253721
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Lymphoma, Metastatic Cancer
Interventions
Melphalan
Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2016
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Sep 13, 2026, 4:44 PM EDT
Completed Phase 2 Interventional Results available

Combined Modality Therapy for Patients With With HIV and Stage I, Stage II, or Stage III Anal Cancer

NCT00324415
View directory record Official record
Conditions
Anal Cancer
Interventions
cetuximab, cisplatin, fluorouracil, radiation therapy
Biological · Drug · Radiation
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years to 120 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
7
States / cities
La Jolla, California • Los Angeles, California • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated May 29, 2025 · Synced Sep 13, 2026, 4:44 PM EDT
Not listed Phase 1 Interventional

Peg-Interferon Alpha 2b Combined With Two Intravenous Broadly HIV-1 Neutralizing Antibodies 3BNC117 and 10-1074 (BEAT-2)

NCT03588715
View directory record Official record
Conditions
HIV, HIV/AIDS, HIV-1 Infection
Interventions
Pegylated Interferon alpha 2b (peg-IFN-α2b), 3BNC117 + 10-1074
Drug
Lead sponsor
Luis Montaner
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 24, 2021 · Synced Sep 13, 2026, 4:44 PM EDT
Completed Phase 3 Interventional Results available

A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease Who Have Reached Therapeutic Goals With Enzyme Replacement Therapy (ENCORE)

NCT00943111
View directory record Official record
Conditions
Gaucher Disease, Type 1
Interventions
Eliglustat tartrate, Imiglucerase
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
17
States / cities
Beverly Hills, California • San Francisco, California • Aurora, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2016 · Synced Sep 13, 2026, 4:44 PM EDT
Completed Phase 4 Interventional

4-Day-A-Week Treatment Plan for HIV Infected Adolescents

NCT00068809
View directory record Official record
Conditions
HIV Infections
Interventions
Short Cycle Antiretroviral Therapy
Procedure
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
12 Years to 24 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
8
States / cities
Los Angeles, California • San Diego, California • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Sep 13, 2026, 4:44 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of AGS-004 During Analytical Treatment Interruption

NCT01069809
View directory record Official record
Conditions
HIV Infection
Interventions
AGS-004, Placebo
Biological
Lead sponsor
Argos Therapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
5
States / cities
Sacramento, California • The Bronx, New York • Chapel Hill, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2017 · Synced Sep 13, 2026, 4:44 PM EDT
Completed No phase listed Observational Results available

Novel Cardiac Magnetic Resonance Imaging to Define a Unique Restrictive Cardiomyopathy in Sickle Cell Disease

NCT02410811
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Cardiac magnetic resonance imaging (CMR)
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 1, 2020 · Synced Sep 13, 2026, 4:44 PM EDT
Completed Phase 2 Interventional Results available

A Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With Progeria

NCT00879034
View directory record Official record
Conditions
Progeria, Hutchinson-Gilford Syndrome
Interventions
Lonafarnib, Zoledronic Acid, Pravastatin
Drug
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Not listed
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Sep 13, 2026, 4:44 PM EDT
Completed Phase 2 Interventional Results available

Treatment Interruption of Natalizumab

NCT01071083
View directory record Official record
Conditions
Relapsing Remitting Multiple Sclerosis
Interventions
natalizumab, interferon beta 1-a, methylprednisolone, IV placebo, glatiramer acetate
Drug · Other
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 60 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
20
States / cities
Cullman, Alabama • San Francisco, California • Fort Collins, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2013 · Synced Sep 13, 2026, 4:44 PM EDT
Completed Phase 2 Interventional Results available

Low-dose Intra-arterial Bevacizumab for Edema and Radiation Necrosis Therapeutic Intervention (LIBERTI)

NCT02819479
View directory record Official record
Conditions
Radiation Necrosis
Interventions
25% Mannitol, Low-dose Intra-arterial Bevacizumab
Drug
Lead sponsor
Norton Healthcare
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
2
States / cities
Lexington, Kentucky • Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated May 23, 2022 · Synced Sep 13, 2026, 4:44 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Family-Based Drug Services for Young Disaster Victims

NCT01859000
View directory record Official record
Conditions
Substance Abuse, Families, Trauma
Interventions
Multidimensional Family Therapy, Group CBT
Other
Lead sponsor
University of Miami
Other
Eligibility
13 Years to 17 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2010
U.S. locations
2
States / cities
Miami, Florida • Luling, Louisiana
Source: ClinicalTrials.gov public record
Updated May 20, 2013 · Synced Sep 13, 2026, 4:44 PM EDT
Completed No phase listed Observational

Effects of Therapeutic HIV Vaccination on Control of HIV After Discontinuation of Anti-HIV Drugs

NCT00050063
View directory record Official record
Conditions
HIV Infections
Interventions
Therapeutic vaccinations from A5058s
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
14
States / cities
Torrance, California • Aurora, Colorado • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 13, 2026, 4:44 PM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Getting to Zero Among HHI MSM in the American South

NCT05075967
View directory record Official record
Conditions
HIV Infections
Interventions
Health Access Coalitions, Social Media, Peer Support, Promoting Human Autonomy Support & Empathy (PHASE)
Behavioral
Lead sponsor
HIV Prevention Trials Network
Network
Eligibility
15 Years and older · Male only
Enrollment
2,700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 13, 2026, 4:44 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Oblimersen Plus Doxorubicin and Docetaxel in Treating Patients With Metastatic or Locally Advanced Breast Cancer

NCT00063934
View directory record Official record
Conditions
Male Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
oblimersen sodium, doxorubicin hydrochloride, docetaxel, filgrastim, pegfilgrastim, therapeutic conventional surgery, pharmacological study, laboratory biomarker analysis
Biological · Drug · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Sep 13, 2026, 4:44 PM EDT